CD274 and triple-negative breast carcinoma: The role of immunotherapy in MBC is currently limited to first-line indication for pembrolizumab in combination with chemotherapy in PD-L1-positive, treatment-naïve triple-negative breast cancer (TNBC) in combination with chemotherapy, whereas its use in later-line settings as single-agent therapy has not shown significant improvement in treatment outcomes (30, 31).